0000950170-24-076871.txt : 20240624
0000950170-24-076871.hdr.sgml : 20240624
20240624170802
ACCESSION NUMBER: 0000950170-24-076871
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240621
FILED AS OF DATE: 20240624
DATE AS OF CHANGE: 20240624
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hassard James
CENTRAL INDEX KEY: 0001799357
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38583
FILM NUMBER: 241065220
MAIL ADDRESS:
STREET 1: 177 E COLORADO BLVD
STREET 2: STE 700
CITY: PASADENA
STATE: CA
ZIP: 91105
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Crinetics Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001658247
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 263744114
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 10222 BARNES CANYON ROAD, BLDG. #2
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-450-6464
MAIL ADDRESS:
STREET 1: 10222 BARNES CANYON ROAD, BLDG. #2
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
ownership.xml
4
X0508
4
2024-06-21
false
0001658247
Crinetics Pharmaceuticals, Inc.
CRNX
0001799357
Hassard James
C/O CRINETICS PHARMACEUTICALS, INC.
6055 LUSK BOULEVARD
SAN DIEGO
CA
92121
false
true
false
false
Chief Commercial Officer
true
Common Stock
2024-06-21
4
M
false
15000
19.73
A
44259
D
Common Stock
2024-06-21
4
S
false
15000
44.66
D
29259
D
Stock option (Right to Buy)
19.73
2024-06-21
4
M
false
15000
0
D
2032-03-10
Common Stock
15000
145000
D
The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $44.66 per share. The range of sales prices on the transaction date was $43.96 to $45.11 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.
The option is exercisable as follows: 25% of the shares subject to the option vest on February 28, 2023, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.
Marc Wilson, as attorney-in-fact
2024-06-24